Welcome to our dedicated page for NEUTRA CORPORATION news (Ticker: NTRR), a resource for investors and traders seeking the latest updates and insights on NEUTRA CORPORATION stock.
Neutra Corp., through its subsidiaries, is a health and wellness lifestyle company specializing in hemp-based health and nutritional products, including CBD tincture, lotion, and salve. Founded in 2011 and based in Sugar Land, Texas, Neutra Corp. is dedicated to developing and marketing natural wellness solutions. The company recently announced a two-year, medium-term management plan to meet the rapidly increasing demand for its specialty health and wellness solutions, consolidating its position as a leader in the sector. Neutra Corp. is focused on expanding its reach through direct-to-consumer opportunities and enhancing its consulting services.
Neutra Corp. (OTC PINK:NTRR) is advancing its Phase-1 clinical trials to evaluate the effectiveness of hemp-based cannabinoids, specifically CBDa, against COVID-19. Building on prior research from Oregon State University, which indicated that CBDa and CBGa could prevent the virus from entering human cells, Neutra aims to demonstrate these cannabinoids' safety and efficacy in combating the virus. Their subsidiary, VIVIS, has partnered with Mercury Clinical Research for these trials. Neutra is also launching a new gummy product infused with CBDa and CBGa, targeting COVID-related health issues.
Neutra Corp. closed 2021 with record success, achieving significant growth by expanding its product line from 10 to over 75 SKUs, including various hemp-based cannabinoids. The company surpassed its entire 2020 revenue of ~$9,600 in just its first quarter of 2021, bringing in more than $73,000 throughout the year. Key developments included acquiring Deity Wellness and launching new sales initiatives across six states. For 2022, Neutra plans to enhance its e-commerce strategies and marketing efforts while conducting clinical trials with Mercury Clinical Research.
Neutra Corp. (OTC PINK:NTRR) has resumed sales efforts through its subsidiary Deity Wellness after a Texas judge ruled in favor of Delta-8's legality. This ruling has alleviated previous uncertainties, leading to a 66% revenue increase from Q2 to Q3 2021. CEO Sydney Jim reported surging interest in their products, including Delta-8 infused gummies and vape cartridges. The ruling allows Deity Wellness to fulfill pending orders and relaunch promotional initiatives that previously garnered 2,000 early orders.
Neutra Corp. subsidiary VIVIS has signed a letter of intent with Mercury Clinical Research to explore the feasibility of a Phase 1 clinical trial testing hemp-based cannabinoids for treating COVID-19. The trial aims to evaluate CBD's effectiveness against SARS-COVID-2, along with other potential health benefits, such as anti-inflammation and pain management. Neutra CEO, Sydney Jim, expressed optimism about the trial's potential global impact. Previous studies indicate that CBD may reduce SARS-CoV-2 infection rates. As of September 2021, COVID-19 has caused nearly 4.6 million global deaths.
Neutra Corp. subsidiary VIVIS has signed a letter of intent with Mercury Clinical Research for a potential Phase 1 clinical trial to test hemp-based cannabinoids in treating COVID-19. This collaboration aims to explore the efficacy of CBD against SARS-CoV-2, with additional investigations into its potential benefits for inflammation, insomnia, appetite regulation, pain management, and anxiety. The CEO emphasized the significant global impact this research could have, especially given the ongoing pandemic, which has claimed nearly 4.6 million lives worldwide.
Neutra Corp. (OTC PINK:NTRR) announced a new pricing strategy for its VIVIS subsidiary, aimed at making its lab-tested CBD products more affordable amid rising inflation. The decision follows an increase in production capacity following the opening of new facilities in Greater Houston. Additionally, VIVIS is set to launch Labor Day sales to further attract consumers. The company is also expanding its market reach, with products now available at Festival Foods in Wisconsin, Restore Hyper Wellness in Houston, and a potential deal for distribution in Mexico.
Neutra Corp. (OTC PINK:NTRR) has made significant strides in securing distribution channels for its subsidiary VIVIS' CBD products. The company has successfully placed VIVIS' products in Festival Foods, a regional supermarket chain, and is set to announce another distribution partnership soon. Discussions are ongoing with well-known distributors and a Clinical Research company for potential acquisition, which could enhance revenue and support product claims. CEO Sydney Jim noted increasing demand for VIVIS products, signaling potential growth ahead.
Neutra Corp. (OTC PINK:NTRR) announced its CBD products will be available at Festival Foods, starting August 9, 2021, at its flagship store in Onalaska, Wisconsin. This deal is the first step towards expanding its presence in all 34 Festival Foods locations. The initiative is supported by Neutra's national sales team and aims to attract other Midwestern retailers. Additionally, the company reported strong early sales for its Deity Wellness subsidiary's Delta-8 products, reflecting growing interest in CBD offerings.
Neutra Corp. (OTC PINK:NTRR) has announced acceptance of its CBD products in a leading Mid-West grocery chain, with initial sales at the flagship location. This milestone comes as a result of Neutra's national sales team efforts and opens doors for future retail opportunities. Recently, the VIVIS brand also started selling products in Pasadena, Texas, with over 2,000 early orders for Delta-8 gummies and vape cartridges recorded in just two days. The company is focused on expanding its market presence in the thriving CBD sector.
Neutra Corp. (OTC PINK:NTRR) announced its Deity Wellness subsidiary has recorded over 2,000 early orders for Delta-8-infused products within just two days of its launch. This surge follows a recent legislative failure to ban hemp-based THC in Texas, highlighting strong pent-up demand among recreational Delta-8 consumers. CEO Sydney Jim emphasized that the acquisition positions Neutra to capture a competitive edge in the growing Delta-8 market, which appeals to customers seeking enjoyment rather than health benefits, setting it apart from traditional CBD users.
FAQ
What is the current stock price of NEUTRA CORPORATION (NTRR)?
What is the market cap of NEUTRA CORPORATION (NTRR)?
What does Neutra Corp. specialize in?
Where is Neutra Corp. headquartered?
When was Neutra Corp. founded?
What products does Neutra Corp. offer?
What recent announcement did Neutra Corp. make?
What sets Neutra Corp. apart in the health and wellness industry?
What is Neutra Corp.'s strategy for growth?
What structural changes has Neutra Corp. made recently?
What upcoming products can consumers expect from Neutra Corp.?
Who is the CEO of Neutra Corp.?
